The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion Pharma GmbH; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion Pharma GmbH; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion Pharma GmbH; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Lawrence Fong
Stock and Other Ownership Interests - Alector; Alector; Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio; TeneoBio
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Janssen Oncology; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; GRAIL; Janssen; Myovant Sciences; Novartis; Pfizer; Sanofi; Tolero Pharmaceuticals
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Xin Gao
Consulting or Advisory Role - Dendreon; Exelixis
Research Funding - Aprea Therapeutics (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Pfizer (Inst); Takeda (Inst)
 
Daniel M. Geynisman
Employment - 2nd.MD
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst); Novartis (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seattle Genetics (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Novartis (Inst); Pfizer (Inst); Vincerx Pharma (Inst)
 
James Fredric Strauss
Leadership - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Merck; Regeneron
Consulting or Advisory Role - Binhui Biopharmaceuticals, Ltd. (Inst); Synlogic (Inst)
 
Kevin Dale Courtney
Stock and Other Ownership Interests - Regeneron (I)
Consulting or Advisory Role - Exelixis
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma; Astellas Pharma (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Proacta (Inst); Stemline Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Seattle Genetics
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Seattle Genetics; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
David James VanderWeele
Consulting or Advisory Role - Clovis Oncology
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Yifah Yaron
Employment - CytomX Therapeutics; Golden State Orthopaedics (I); Harpoon Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Exelixis; Global Blood Therapeutics; Harpoon therapeutics
 
Che-Leung Law
Employment - Harpoon therapeutics
Leadership - Harpoon therapeutics
Stock and Other Ownership Interests - Harpoon Therapeutics; Seattle Genetics
Consulting or Advisory Role - VelosBio
Patents, Royalties, Other Intellectual Property - Seattle Genetics
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme; Xencor
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seattle Genetics (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)